Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.18, Iss.3, 2013-09, pp. : 375-391

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sodium-Glucose Co-Transporter 2 Inhibition in Diabetes Treatment: Current Evidence and Future Perspectives

Current Pharmaceutical Design, Vol. 20, Iss. 22, 2014-05 ,pp. : 3647-3656

Bentham Science Publishers

Access to resources Recommend Favorite

Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’

Current Pharmaceutical Design, Vol. 16, Iss. 34, 2010-11 ,pp. : 3830-3838

Bentham Science Publishers

Access to resources Recommend Favorite

Sodium-Glucose Co-Transport Inhibitors: Progress and Therapeutic Potential in Type 2 Diabetes Mellitus

By Neumiller Joshua J.

Drugs, Vol. 70, Iss. 4, 2010-03 ,pp. : 377-385

Adis International

Access to resources Recommend Favorite

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

By Washburn William N

Expert Opinion on Therapeutic Patents, Vol. 19, Iss. 11, 2009-11 ,pp. : 1485-1499

Informa Healthcare

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M Younk Lisa M Davis Stephen N

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite